ASX - By Stock
|
PAA |
Re:
what odds of house deposit
|
|
Ribw
|
14 |
3.3K |
3 |
22/03/24 |
22/03/24 |
ASX - By Stock
|
14
|
3.3K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
what odds of house deposit
|
|
Ribw
|
14 |
3.3K |
0 |
21/03/24 |
21/03/24 |
ASX - By Stock
|
14
|
3.3K
|
0
|
|
ASX - By Stock
|
PAA |
Re:
what odds of house deposit
|
|
Ribw
|
14 |
3.3K |
0 |
21/03/24 |
21/03/24 |
ASX - By Stock
|
14
|
3.3K
|
0
|
|
ASX - By Stock
|
PAA |
Re:
what odds of house deposit
|
|
Ribw
|
14 |
3.3K |
0 |
21/03/24 |
21/03/24 |
ASX - By Stock
|
14
|
3.3K
|
0
|
|
ASX - By Stock
|
PAA |
what odds of house deposit
|
|
Ribw
|
14 |
3.3K |
18 |
21/03/24 |
21/03/24 |
ASX - By Stock
|
14
|
3.3K
|
18
|
|
ASX - By Stock
|
PAA |
Re:
PharmAust media thread
|
|
Ribw
|
304 |
71K |
9 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
304
|
71K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
share dumping
|
|
Ribw
|
17 |
3.7K |
6 |
18/03/24 |
18/03/24 |
ASX - By Stock
|
17
|
3.7K
|
6
|
|
ASX - By Stock
|
PAA |
share dumping
|
|
Ribw
|
17 |
3.7K |
10 |
18/03/24 |
18/03/24 |
ASX - By Stock
|
17
|
3.7K
|
10
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Ribw
|
971 |
226K |
26 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
971
|
226K
|
26
|
|
ASX - By Stock
|
PAA |
Re:
Amylyx class action Relyvrio
|
|
Ribw
|
58 |
14K |
10 |
11/03/24 |
11/03/24 |
ASX - By Stock
|
58
|
14K
|
10
|
|
ASX - By Stock
|
PAA |
Re:
Amylyx class action Relyvrio
|
|
Ribw
|
58 |
14K |
6 |
11/03/24 |
11/03/24 |
ASX - By Stock
|
58
|
14K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Amylyx class action Relyvrio
|
|
Ribw
|
58 |
14K |
6 |
11/03/24 |
11/03/24 |
ASX - By Stock
|
58
|
14K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Amylyx class action Relyvrio
|
|
Ribw
|
58 |
14K |
17 |
11/03/24 |
11/03/24 |
ASX - By Stock
|
58
|
14K
|
17
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Ribw
|
971 |
226K |
5 |
06/03/24 |
06/03/24 |
ASX - By Stock
|
971
|
226K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Sparks Valuation Pharmaust
|
|
Ribw
|
111 |
33K |
8 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
111
|
33K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Investor webinar - Phase 1 MND Study Top-Line Results
|
|
Ribw
|
209 |
45K |
7 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
209
|
45K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
Ribw
|
114 |
30K |
1 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
114
|
30K
|
1
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Extension Study Begins, Analysis Suggests Survival Benefit
|
|
Ribw
|
197 |
48K |
9 |
19/02/24 |
19/02/24 |
ASX - By Stock
|
197
|
48K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Extension Study Begins, Analysis Suggests Survival Benefit
|
|
Ribw
|
197 |
48K |
8 |
19/02/24 |
19/02/24 |
ASX - By Stock
|
197
|
48K
|
8
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA 2022 , Human Trials , Covid , MND , Oncology , HVTL-1, K9 Phase III
|
|
Ribw
|
1.4K |
365K |
7 |
10/08/22 |
10/08/22 |
ASX - By Stock
|
1.4K
|
365K
|
7
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA 2022 , Human Trials , Covid , MND , Oncology , HVTL-1, K9 Phase III
|
|
Ribw
|
1.4K |
365K |
10 |
09/08/22 |
09/08/22 |
ASX - By Stock
|
1.4K
|
365K
|
10
|
|
ASX - By Stock
|
PAA |
Re:
Latest JP Equity Research Report - July 2022
|
|
Ribw
|
36 |
8.7K |
17 |
28/07/22 |
28/07/22 |
ASX - By Stock
|
36
|
8.7K
|
17
|
|
ASX - By Stock
|
PAA |
Re:
Latest JP Equity Research Report - July 2022
|
|
Ribw
|
36 |
8.7K |
18 |
25/07/22 |
25/07/22 |
ASX - By Stock
|
36
|
8.7K
|
18
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appendix 4C and Quarterly Update
|
|
Ribw
|
44 |
10K |
17 |
20/07/22 |
20/07/22 |
ASX - By Stock
|
44
|
10K
|
17
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Notification of cessation of securities - PAA
|
|
Ribw
|
93 |
22K |
10 |
04/07/22 |
04/07/22 |
ASX - By Stock
|
93
|
22K
|
10
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAA appoints trial manager & receives $200k from FightMND
|
|
Ribw
|
21 |
5.2K |
23 |
08/04/22 |
08/04/22 |
ASX - By Stock
|
21
|
5.2K
|
23
|
|
ASX - By Stock
|
ADO |
Re:
Ann: TGA Registration Update
|
|
Ribw
|
2.4K |
721K |
8 |
13/01/22 |
13/01/22 |
ASX - By Stock
|
2.4K
|
721K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Leiden Testing Indicates MPL SARS-CoV-2 Antiviral Activity
|
|
Ribw
|
732 |
141K |
3 |
26/04/21 |
26/04/21 |
ASX - By Stock
|
732
|
141K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Leiden Testing Indicates MPL SARS-CoV-2 Antiviral Activity
|
|
Ribw
|
732 |
141K |
4 |
07/04/21 |
07/04/21 |
ASX - By Stock
|
732
|
141K
|
4
|
|
ASX - By Stock
|
IBX |
Re:
Ann: Imagion Biosystems March 2021 Investor Newsletter
|
|
Ribw
|
98 |
40K |
0 |
06/04/21 |
06/04/21 |
ASX - By Stock
|
98
|
40K
|
0
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Update on Phase IIb Clinical Trial of Monepantel in Pet Dogs
|
|
Ribw
|
56 |
11K |
8 |
30/03/21 |
30/03/21 |
ASX - By Stock
|
56
|
11K
|
8
|
|
ASX - By Stock
|
ADO |
Re:
ADO Charting and Technical Analysis
|
|
Ribw
|
9.1K |
2.7M |
7 |
17/02/21 |
17/02/21 |
ASX - By Stock
|
9.1K
|
2.7M
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Virtual Investor Briefing
|
|
Ribw
|
113 |
22K |
6 |
12/02/21 |
12/02/21 |
ASX - By Stock
|
113
|
22K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appendix 4C and Quarterly Update
|
|
Ribw
|
106 |
18K |
5 |
05/02/21 |
05/02/21 |
ASX - By Stock
|
106
|
18K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appendix 4C and Quarterly Update
|
|
Ribw
|
106 |
18K |
16 |
27/01/21 |
27/01/21 |
ASX - By Stock
|
106
|
18K
|
16
|
|
ASX - By Stock
|
PAA Biotech |
Re:
Covi-Pantel . NZ Trader Release
|
|
Ribw
|
1.4K |
309K |
16 |
26/01/21 |
26/01/21 |
ASX - By Stock
|
1.4K
|
309K
|
16
|
|
ASX - By Stock
|
IBX |
Re:
Interesting
|
|
Ribw
|
5.5K |
1.9M |
4 |
22/01/21 |
22/01/21 |
ASX - By Stock
|
5.5K
|
1.9M
|
4
|
|
ASX - By Stock
|
PAA Biotech |
Re:
Biomass Reactor - Insights and Markets
|
|
Ribw
|
10 |
2.7K |
9 |
22/01/21 |
22/01/21 |
ASX - By Stock
|
10
|
2.7K
|
9
|
|
ASX - By Stock
|
PAA Biotech |
Re:
Covi-Pantel . NZ Trader Release
|
|
Ribw
|
1.4K |
309K |
10 |
15/01/21 |
15/01/21 |
ASX - By Stock
|
1.4K
|
309K
|
10
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Leiden University Medical Centre Monepantel COVID-19 Testing
|
|
Ribw
|
105 |
21K |
6 |
10/01/21 |
10/01/21 |
ASX - By Stock
|
105
|
21K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appendix 2A & s708 notice
|
|
Ribw
|
14 |
3.1K |
5 |
05/01/21 |
05/01/21 |
ASX - By Stock
|
14
|
3.1K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAA Commences Manufacture of GMP-Grade MPL for Human Trials
|
|
Ribw
|
14 |
3.9K |
5 |
23/12/20 |
23/12/20 |
ASX - By Stock
|
14
|
3.9K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAA Commences Manufacture of GMP-Grade MPL for Human Trials
|
|
Ribw
|
14 |
3.9K |
6 |
23/12/20 |
23/12/20 |
ASX - By Stock
|
14
|
3.9K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Epichem Awarded Contract Extension from DNDi
|
|
Ribw
|
12 |
3.5K |
8 |
21/12/20 |
21/12/20 |
ASX - By Stock
|
12
|
3.5K
|
8
|
|
ASX - By Stock
|
IBX |
Re:
Ann: First-in-human study update - Study open for enrolment
|
|
Ribw
|
157 |
61K |
5 |
16/12/20 |
16/12/20 |
ASX - By Stock
|
157
|
61K
|
5
|
|
ASX - By Stock
|
IBX |
Re:
Ann: First-in-human study update - Study open for enrolment
|
|
Ribw
|
157 |
61K |
9 |
16/12/20 |
16/12/20 |
ASX - By Stock
|
157
|
61K
|
9
|
|
ASX - By Stock
|
IBX |
Re:
Ann: Issue of Rights & Options under EIP
|
|
Ribw
|
19 |
6.3K |
2 |
15/12/20 |
15/12/20 |
ASX - By Stock
|
19
|
6.3K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
Some scientific inspiration
|
|
Ribw
|
27 |
4.9K |
4 |
11/12/20 |
11/12/20 |
ASX - By Stock
|
27
|
4.9K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Some scientific inspiration
|
|
Ribw
|
27 |
4.9K |
8 |
11/12/20 |
11/12/20 |
ASX - By Stock
|
27
|
4.9K
|
8
|
|
ASX - By Stock
|
IBX |
Re:
Human Trial
|
|
Ribw
|
247 |
98K |
7 |
09/12/20 |
09/12/20 |
ASX - By Stock
|
247
|
98K
|
7
|
|